BELLUS Health Inc. (BLU)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.46-0.35 (-6.02%)
At close: 1:00PM EST
5.44 -0.02 (-0.37%)
After hours: 02:39PM EST
After hours: 02:39PM EST
| Previous close | 5.81 |
| Open | 5.87 |
| Bid | 5.42 x 1800 |
| Ask | 5.68 x 3000 |
| Day's range | 5.42 - 5.85 |
| 52-week range | 2.60 - 7.65 |
| Volume | 510,515 |
| Avg. volume | 2,484,803 |
| Market cap | 439.679M |
| Beta (5Y monthly) | -0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.81 |
- Zacks
Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
- Zacks
Bellus Health (BLU) Reports Q3 Loss
Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
LAVAL, Quebec, November 10, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021.
© 2021 Yahoo. All rights reserved.
